258836-03-2

Basic information

• Product Name: (1-Methylcyclohexan-1-yl)carbonyloxymethyl(1S,5R,6S)-2-[7-(N,N-dimethylcarbamoyl)acetylimidazo[5,1-b]thiazol-2-yl]-6-((1R)-1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate
• CAS NO: 258836-03-2
• Molecular Weight: 600.693
• Mol File: 258836-03-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (1-Methylcyclohexan-1-yl)carbonyloxymethyl(1S,5R,6S)-2-[7-(N,N-dimethylcarbamoyl)acetylimidazo[5,1-b]thiazol-2-yl]-6-((1R)-1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (1-Methylcyclohexan-1-yl)carbonyloxymethyl(1S,5R,6S)-2-[7-(N,N-dimethylcarbamoyl)acetylimidazo[5,1-b]thiazol-2-yl]-6-((1R)-1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate(258836-03-2)
• EPA Substance Registry System: (1-Methylcyclohexan-1-yl)carbonyloxymethyl(1S,5R,6S)-2-[7-(N,N-dimethylcarbamoyl)acetylimidazo[5,1-b]thiazol-2-yl]-6-((1R)-1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate(258836-03-2)

Safety Data

• Hazardous Substances Data: 258836-03-2(Hazardous Substances Data)

Upstream product

• 251-89-8 imidazo[5,1-b]thiazole 
• 258840-34-5 4-nitrobenzyl(1S,5R,6S)-2-[7-(N,N-dimethylcarbamoyl)acetylimidazo[5,1-b]thiazol-2-yl]-6-((1R)-1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate 
• 258839-16-6 7-N,N-Dimethylcarbamoylacetyl-2-(tri-n-butylstannyl)imidazo[5,1-b]thiazole 
• 258839-18-8 7-N,N-dimethylcarbamoylacetylimidazo[5,1-b]thiazole 
• 185747-98-2 7-formylimidazo[5,1-b]thiazole 
• 258836-01-0 Sodium(1S,5R,6S)-2-[7-(N,N-dimethylcarbamoyl)-acetylimidazo[5,1-b]thiazol-2-yl]-6-((1R)-1-hydroxyethyl)-1-methyl-1-carbapen-2-em-3-carboxylate 
• 126531-59-7 1-methylcyclohexylcarbonyloxymethyl iodide 

Relevant articles and documents

Carbapenem derivatives

Disclosed is a novel carbapenem derivative having a substituted imidazo[5,1-b]thiazole group at the 2-position on the carbapenem ring have high anti-microbial activities against β-lactamase producing bacteria, MRSA, resistant-Pseudomonas aeruginosa, PRSP, enterococci, and influenza, and high stabilities to DHP-1. According to the present invention, there is provided a compound represented by the formula (I), or a pharmacologically acceptable salt thereof or an ester at the 3-position on the carbapenem ring thereof: